Sodium–glucose cotransporter-2 inhibitors in frailty: current evidence and clinical recommendations
Posted 24 Jul 2026
Dr Lisa Devine reviews how sodium-glucose cotransporter-2 inhibitors can benefit people living with frailty across heart failure, chronic kidney disease and type 2 diabetes, weighing key safety considerations.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page